Richard Alan Lafayette, MD

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: 052514 · 552746 · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lafayette’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence G62856 · Current

Licensed to practise in California · since 1988 · expires 2027-12-31 · New York Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$97,082

Medicare paid this office $97,082 for 233 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Dialysis services, 2-3 physician visits per month (20 years or older)	22	$29,828	$266
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	58	$9,329	$71
Return visit (30+ min)	63	$8,013	$80
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	44	$7,766	$106
Return visit (30+ min)	45	$6,929	$112

See all 11 services

Sort by

Every Original Medicare service billed

Dialysis services, 2-3 physician visits per month (20 years or older)	22	$29,828	$266
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	58	$9,329	$71
Return visit (30+ min)	63	$8,013	$80
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	44	$7,766	$106
Return visit (30+ min)	45	$6,929	$112
Dialysis procedure including 1 evaluation	19	$5,998	$79
Hemodialysis procedure with physician evaluation	36	$3,806	$63
Long return visit (40+ min)	21	$3,228	$124
Dialysis services, 1 physician visit per month (20 years or older)	13	$3,013	$188
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	23	$2,682	$117
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$1,862	$155

Who their Medicare patients are

233 Original Medicare patients in 2024. Average age 69 · Under 65 27% · 85 and older 11% · Women 43% · Also on Medicaid 47% · Health risk score 5.67. Above the middle of the specialty; the typical nephrology clinician is at 4.01.

Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 63% · Heart failure 53% · Coronary heart disease 48% · Atrial fibrillation 36% · Depression 24% · Cancer 23% · COPD 23% · Dementia 21% · Stroke 20%.

The office billed $411,417, Medicare allowed $124,282 and paid $97,082; for 787 services of 24 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	233	787	69	5.67	$411,417	$97,082
2023	269	847	71	5.31	$450,613	$107,333
2022	276	1,098	70	4.89	$557,500	$133,936
2021	272	1,225	68	4.70	$584,757	$140,839
2020	285	1,192	68	4.83	$629,236	$142,694
2019	249	893	69	4.61	$377,682	$97,991
2018	322	1,124	66	4.70	$440,758	$116,704
2017	319	1,174	67	4.34	$410,693	$110,154
2016	350	1,294	66	4.46	$459,094	$121,058
2015	354	1,234	66	4.67	$434,327	$122,683
2014	339	1,141	66	4.56	$411,172	$116,144
2013	339	1,282	66	4.31	$425,526	$119,054

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 11 services

Sort by

Original Medicare services billed in 2023

Dialysis services, 2-3 physician visits per month (20 years or older)	28	$27,288	$276
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	93	$14,957	$73
Return visit (30+ min)	101	$14,363	$80
Dialysis services, 4 or more physician visits per month (20 years or older)	17	$11,241	$331
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	49	$7,679	$108
Dialysis procedure including 1 evaluation	19	$5,404	$81
Dialysis services, 1 physician visit per month (20 years or older)	18	$4,222	$192
Initial hospital care with moderate level of medical decision making at least 75 minutes	21	$3,518	$160
Hemodialysis procedure with physician evaluation	30	$3,281	$66
Long return visit (40+ min)	18	$2,527	$133
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	20	$2,391	$120

2022: 12 services

Sort by

Original Medicare services billed in 2022

Dialysis services, 2-3 physician visits per month (20 years or older)	32	$49,560	$277
Return visit (30+ min)	104	$18,913	$81
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	79	$12,092	$64
Dialysis services, 4 or more physician visits per month (20 years or older)	17	$10,074	$336
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	57	$8,362	$93
Dialysis services, 1 physician visit per month (20 years or older)	13	$4,819	$193
Dialysis procedure including 1 evaluation	21	$4,350	$81
Hemodialysis procedure with physician evaluation	39	$4,197	$66
Long return visit (40+ min)	17	$2,753	$125
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,345	$180
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	12	$1,472	$123
Short return visit (20+ min)	12	$760	$54

2021: 13 services

Sort by

Original Medicare services billed in 2021

Dialysis services, 2-3 physician visits per month (20 years or older)	32	$50,916	$281
Return visit (30+ min)	99	$18,022	$83
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	80	$10,030	$66
Dialysis services, 4 or more physician visits per month (20 years or older)	14	$8,477	$339
Dialysis services, 1 physician visit per month (20 years or older)	23	$7,038	$190
Dialysis procedure including 1 evaluation	25	$6,741	$81
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	43	$6,058	$92
Hemodialysis procedure with physician evaluation	35	$3,037	$66
Initial hospital care with moderate level of medical decision making at least 75 minutes	16	$2,961	$185
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	25	$2,669	$107
Long return visit (40+ min)	18	$2,638	$115
Telephone medical discussion with physician, 21-30 minutes	14	$1,764	$84
Short return visit (20+ min)	21	$1,679	$60

2020: 14 services

Sort by

Original Medicare services billed in 2020

Dialysis services, 2-3 physician visits per month (20 years or older)	29	$34,580	$223
Dialysis services, 1 physician visit per month (20 years or older)	32	$12,643	$169
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	80	$12,365	$68
Return visit (30+ min)	91	$10,570	$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	57	$10,194	$97
Dialysis services, 4 or more physician visits per month (20 years or older)	19	$9,208	$271
Dialysis procedure including 1 evaluation	26	$8,379	$82
Initial hospital care with moderate level of medical decision making at least 75 minutes	35	$6,557	$187
Hemodialysis procedure with physician evaluation	34	$4,588	$68
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	25	$3,260	$130
Long return visit (40+ min)	21	$2,921	$104
Telephone medical discussion with physician, 21-30 minutes	16	$1,602	$73
Return visit (30+ min)	20	$1,436	$72
Short return visit (20+ min)	14	$729	$49

2019: 11 services

Sort by

Original Medicare services billed in 2019

Dialysis services, 1 physician visit per month (20 years or older)	32	$22,710	$169
Dialysis services, 2-3 physician visits per month (20 years or older)	21	$14,235	$219
Home dialysis services per month (20 years or older)	12	$13,774	$212
Return visit (30+ min)	109	$12,697	$64
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	59	$9,902	$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	36	$5,943	$94
Initial hospital care with moderate level of medical decision making at least 75 minutes	23	$4,221	$184
Hemodialysis procedure with physician evaluation	23	$2,655	$66
Long return visit (40+ min)	21	$2,322	$93
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	17	$2,104	$124
Hospital discharge day management, 30 minutes or less	11	$725	$66

2018: 12 services

Sort by

Original Medicare services billed in 2018

Dialysis services, 1 physician visit per month (20 years or older)	31	$27,662	$166
Return visit (30+ min)	125	$17,206	$67
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	101	$15,666	$63
Dialysis services, 2-3 physician visits per month (20 years or older)	21	$12,026	$211
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	35	$5,149	$94
Dialysis procedure including 1 evaluation	28	$4,400	$71
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$4,366	$182
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	33	$4,155	$122
Long return visit (40+ min)	25	$2,891	$96
Hemodialysis procedure with physician evaluation	30	$2,878	$61
Hospital discharge day management, 30 minutes or less	13	$869	$67
Short return visit (20+ min)	20	$737	$35

2017: 12 services

Sort by

Original Medicare services billed in 2017

Dialysis services, 1 physician visit per month (20 years or older)	34	$29,919	$167
Return visit (30+ min)	137	$18,178	$64
Dialysis services, 2-3 physician visits per month (20 years or older)	16	$15,403	$217
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	88	$13,086	$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	42	$6,336	$93
Dialysis procedure including 1 evaluation	20	$4,053	$78
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	31	$3,783	$122
Initial hospital care with moderate level of medical decision making at least 75 minutes	18	$3,263	$181
Hemodialysis procedure with physician evaluation	27	$2,318	$63
Long return visit (40+ min)	12	$1,395	$100
Short return visit (20+ min)	26	$1,297	$41
Hospital discharge day management, 30 minutes or less	14	$928	$66

2016: 11 services

Sort by

Original Medicare services billed in 2016

Dialysis services, 1 physician visit per month (20 years or older)	42	$28,946	$166
Return visit (30+ min)	135	$17,934	$63
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	102	$16,911	$64
Dialysis services, 2-3 physician visits per month (20 years or older)	19	$16,389	$216
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	56	$8,981	$93
Initial hospital care with moderate level of medical decision making at least 75 minutes	36	$6,670	$180
Dialysis procedure including 1 evaluation	19	$3,753	$78
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	27	$3,402	$121
Hemodialysis procedure with physician evaluation	20	$1,875	$65
Short return visit (20+ min)	34	$1,732	$41
Hospital discharge day management, 30 minutes or less	12	$789	$66

2015: 9 services

Sort by

Original Medicare services billed in 2015

Dialysis services, 1 physician visit per month (20 years or older)	40	$25,697	$169
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	113	$20,686	$64
Return visit (30+ min)	139	$20,007	$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	94	$18,213	$91
Dialysis services, 2-3 physician visits per month (20 years or older)	19	$13,787	$215
Initial hospital care with moderate level of medical decision making at least 75 minutes	42	$7,782	$181
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	28	$3,523	$121
Long return visit (40+ min)	21	$2,184	$95
Short return visit (20+ min)	21	$1,047	$37

2014: 10 services

Sort by

Original Medicare services billed in 2014

Dialysis services, 1 physician visit per month (20 years or older)	38	$23,601	$167
Dialysis services, 2-3 physician visits per month (20 years or older)	22	$19,586	$208
Return visit (30+ min)	140	$19,228	$65
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	98	$16,391	$62
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	81	$15,157	$91
Initial hospital care with moderate level of medical decision making at least 75 minutes	31	$5,576	$180
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	30	$3,465	$115
Long return visit (40+ min)	20	$2,351	$98
New patient visit (60+ min)	15	$2,128	$142
Short return visit (20+ min)	18	$910	$41

2013: 10 services

Sort by

Original Medicare services billed in 2013

Dialysis services, 2-3 physician visits per month (20 years or older)	18	$21,502	$215
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	110	$20,694	$63
Return visit (30+ min)	145	$19,494	$61
Dialysis services, 1 physician visit per month (20 years or older)	33	$17,794	$168
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	82	$12,543	$90
Initial hospital care with moderate level of medical decision making at least 75 minutes	43	$7,547	$176
Long return visit (40+ min)	29	$3,596	$95
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	26	$3,091	$119
New patient visit (60+ min)	17	$2,240	$132
Short return visit (20+ min)	23	$1,054	$41

Medicaid work

$2,253 in 2024

Medicaid paid $2,253 for 65 billed services this clinician did in 2024, up to 19 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	42	$1,413
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	23	$840

Sort by

Medicaid work by year

2024	65	2	19	$2,253
2023	76	2	13	$2,636
2022	167	3	18	$5,867
2021	135	3	16	$5,294
2020	155	4	22	$6,649
2019	124	2	19	$3,970
2018	59	2	13	$992

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	59	$1,783
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	17	$853

2022

Sort by

Largest Medicaid services in 2022

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	134	$4,694
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	21	$852
Return visit (30+ min)	12	$321

2021

Sort by

Largest Medicaid services in 2021

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	98	$3,446
Return visit (30+ min)	25	$1,054
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	12	$794

2020

Sort by

Largest Medicaid services in 2020

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	82	$2,881
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	48	$2,426
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month	12	$944
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month	13	$398

2019

Sort by

Largest Medicaid services in 2019

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	97	$3,003
Return visit (30+ min)	27	$967

2018

Sort by

Largest Medicaid services in 2018

SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES	45	$696
Return visit (30+ min)	14	$295

Drugs they prescribed that Part D paid

$164,770

Pharmacies billed $164,770 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 3% of their Part D prescriptions (37 of 1,426) in 2024. A higher opioid share than 9 in 10 peers; the typical nephrology clinician is at 0%.

1,271 generic and 155 brand-name prescriptions · $164,770 in drug cost · 12 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Farxiga	29	$28,231	$973
Eliquis	28	$19,514	$697
Procrit	11	$16,115	$1,465
Envarsus Xr	11	$8,831	$803
Tacrolimus	35	$7,265	$208

See all 42 drugs

Sort by

Every Part D drug this clinician prescribed

Farxiga	29	$28,231	$973
Eliquis	28	$19,514	$697
Procrit	11	$16,115	$1,465
Envarsus Xr	11	$8,831	$803
Tacrolimus	35	$7,265	$208
Jardiance	11	$6,120	$556
Sevelamer Carbonate	27	$4,673	$173
Neoral	13	$4,077	$314
Mycophenolate Mofetil	29	$3,829	$132
Mycophenolic Acid	13	$1,398	$108
Nifedipine Er	18	$1,392	$77
Amlodipine Besylate	143	$735	$5
Cinacalcet	16	$719	$45
Atorvastatin	95	$651	$7
Colchicine	15	$557	$37
Hydrocodone-Acetaminophen	18	$531	$29
Losartan	75	$517	$7
Torsemide	13	$513	$39
Metoprolol	24	$497	$21
Prednisone	47	$455	$10
Carvedilol	44	$403	$9
Rosuvastatin	26	$398	$15
Albuterol Sulfate Hfa	13	$379	$29
Allopurinol	31	$343	$11
Chlorthalidone	14	$329	$23
Bumetanide	12	$307	$26
Omeprazole	30	$304	$10
Oxycodone	14	$285	$20
Lorazepam	22	$280	$13
Metformin	22	$184	$8
Lisinopril	42	$179	$4
Tamsulosin	23	$158	$7
Furosemide	32	$155	$5
Metoprolol	32	$129	$4
Simvastatin	21	$93	$4
Zolpidem	19	$91	$5
Levothyroxine	14	$75	$5
Levetiracetam	12	$72	$6
Hydralazine	15	$67	$4
Famotidine	15	$51	$3
Atenolol	26	$29	$1
Hydrochlorothiazide	14	$3	$0

Year by year

Sort by

Part D prescribing by year

2024	1,426	115	3% (37)	11%	$164,770
2023	1,499	121	2% (32)	None	$236,742
2022	1,824	136	6% (100)	8%	$197,887
2021	1,708	136	5% (87)	None	$171,647
2020	1,607	127	4% (62)	None	$163,726
2019	1,798	122	3% (49)	11%	$225,143
2018	1,785	140	4% (62)	None	$233,124
2017	1,963	119	2% (36)	None	$340,155
2016	2,173	132	1% (11)	None	$426,218
2015	2,404	137	1% (26)	19%	$346,464
2014	2,296	132	2% (46)	22%	$373,455
2013	2,489	125	2% (41)	29%	$369,697

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 42 drugs

Sort by

Part D drugs prescribed in 2023

Renvela	18	$44,445	$2,469
Farxiga	18	$31,953	$1,775
Eliquis	29	$24,568	$847
Velphoro	11	$18,941	$1,722
Tacrolimus	30	$2,733	$91
Mycophenolic Acid	12	$2,470	$206
Clonidine	14	$2,251	$161
Amlodipine Besylate	142	$1,870	$13
Mycophenolate Mofetil	30	$1,698	$57
Atorvastatin	92	$1,581	$17
Midodrine	14	$1,423	$102
Bumetanide	13	$1,405	$108
Calcium Acetate	15	$1,151	$77
Torsemide	23	$1,116	$49
Carvedilol	63	$904	$14
Losartan	58	$858	$15
Nifedipine Er	11	$830	$75
Calcitriol	15	$660	$44
Lisinopril	27	$644	$24
Tamsulosin	37	$610	$16
Metoprolol	26	$601	$23
Allopurinol	42	$592	$14
Omeprazole	42	$456	$11
Ondansetron Odt	12	$450	$38
Hydralazine	27	$443	$16
Prednisone	57	$426	$7
Furosemide	31	$393	$13
Levetiracetam	12	$386	$32
Metoprolol	37	$378	$10
Atenolol	26	$377	$14
Labetalol	11	$362	$33
Metformin	19	$307	$16
Chlorthalidone	11	$272	$25
Zolpidem	14	$267	$19
Levothyroxine	20	$262	$13
Simvastatin	22	$227	$10
Pantoprazole	18	$215	$12
Rosuvastatin	21	$179	$9
Oxycodone	13	$173	$13
Lorazepam	13	$139	$11
Famotidine	16	$99	$6
Cephalexin	12	$53	$4

2022: 49 drugs

Sort by

Part D drugs prescribed in 2022

Eliquis	30	$24,345	$812
Voriconazole	12	$20,065	$1,672
Farxiga	11	$18,824	$1,711
Entresto	14	$9,346	$668
Sevelamer Carbonate	29	$6,827	$235
Tacrolimus	44	$5,194	$118
Midodrine	24	$3,403	$142
Calcium Acetate	31	$3,090	$100
Potassium Citrate Er	14	$2,988	$213
Eplerenone	15	$2,132	$142
Atorvastatin	137	$2,007	$15
Labetalol	13	$1,736	$134
Mycophenolate Mofetil	23	$1,510	$66
Hydromorphone	13	$1,267	$97
Entecavir	12	$1,254	$104
Losartan	67	$1,222	$18
Amlodipine Besylate	174	$1,164	$7
Metoprolol	27	$750	$28
Calcitriol	18	$688	$38
Carvedilol	60	$584	$10
Torsemide	13	$546	$42
Allopurinol	43	$544	$13
Omeprazole	35	$516	$15
Prednisone	58	$503	$9
Nifedipine Er	15	$492	$33
Chlorthalidone	22	$481	$22
Tamsulosin	34	$436	$13
Furosemide	42	$421	$10
Potassium Chloride	16	$414	$26
Hydralazine	32	$402	$13
Hydrocortisone	16	$387	$24
Pantoprazole	19	$383	$20
Isosorbide Mononitrate Er	20	$364	$18
Lisinopril	39	$362	$9
Methadone	22	$313	$14
Levothyroxine	14	$297	$21
Naratriptan	12	$296	$25
Zolpidem	38	$264	$7
Tramadol	42	$256	$6
Gabapentin	16	$253	$16
Hydrocodone-Acetaminophen	11	$247	$22
Diltiazem 24hr Er (Cd)	16	$238	$15
Levetiracetam	15	$176	$12
Atenolol	28	$160	$6
Simvastatin	25	$160	$6
Metoprolol	19	$152	$8
Alendronate	12	$127	$11
Lorazepam	13	$101	$8
Cephalexin	12	$51	$4

2021: 46 drugs

Sort by

Part D drugs prescribed in 2021

Renvela	13	$20,334	$1,564
Eliquis	19	$13,107	$690
Tacrolimus	42	$12,149	$289
Sevelamer Carbonate	41	$8,460	$206
Entresto	11	$6,774	$616
Mycophenolate Mofetil	41	$3,522	$86
Labetalol	13	$3,362	$259
Voriconazole	13	$2,764	$213
Fentanyl	11	$2,012	$183
Potassium Citrate Er	11	$1,896	$172
Eplerenone	16	$1,676	$105
Losartan	89	$1,588	$18
Midodrine	22	$1,271	$58
Amlodipine Besylate	168	$1,217	$7
Metoprolol	31	$1,170	$38
Atorvastatin	111	$1,128	$10
Nifedipine Er	15	$1,090	$73
Ondansetron Odt	11	$924	$84
Carvedilol	64	$916	$14
Calcitriol	22	$734	$33
Tamsulosin	23	$628	$27
Entecavir	11	$582	$53
Furosemide	52	$562	$11
Allopurinol	47	$557	$12
Chlorthalidone	33	$542	$16
Pantoprazole	22	$536	$24
Hydromorphone	12	$519	$43
Prednisone	52	$504	$10
Potassium Chloride	15	$470	$31
Omeprazole	25	$444	$18
Torsemide	13	$402	$31
Gabapentin	18	$399	$22
Zolpidem	33	$349	$11
Spironolactone	12	$306	$26
Methadone	18	$283	$16
Levothyroxine	12	$283	$24
Tramadol	33	$197	$6
Metoprolol	32	$191	$6
Simvastatin	30	$183	$6
Hydralazine	15	$160	$11
Lisinopril	27	$124	$5
Alendronate	15	$108	$7
Atenolol	23	$101	$4
Levetiracetam	13	$93	$7
Hydrocodone-Acetaminophen	11	$93	$8
Lorazepam	11	$55	$5

2020: 47 drugs

Sort by

Part D drugs prescribed in 2020

Renvela	16	$26,184	$1,637
Lanthanum Carbonate	16	$16,242	$1,015
Sevelamer Carbonate	44	$10,917	$248
Eliquis	15	$10,155	$677
Tacrolimus	42	$8,431	$201
Cinacalcet	15	$7,310	$487
Calcium Acetate	23	$3,415	$148
Mycophenolate Mofetil	28	$3,087	$110
Midodrine	18	$2,122	$118
Fentanyl	11	$2,050	$186
Labetalol	13	$1,405	$108
Gabapentin	30	$878	$29
Losartan	53	$803	$15
Calcitriol	14	$755	$54
Amlodipine Besylate	112	$688	$6
Atorvastatin	79	$629	$8
Torsemide	20	$619	$31
Chlorthalidone	33	$591	$18
Metoprolol	15	$586	$39
Prednisone	66	$530	$8
Azathioprine	14	$495	$35
Allopurinol	43	$493	$11
Carvedilol	55	$459	$8
Potassium Chloride	11	$436	$40
Tamsulosin	21	$432	$21
Furosemide	45	$422	$9
Omeprazole	44	$399	$9
Spironolactone	16	$287	$18
Oxybutynin Chloride Er	12	$258	$22
Simvastatin	34	$245	$7
Diclofenac	13	$241	$19
Entecavir	13	$220	$17
Famotidine	19	$200	$11
Lisinopril	46	$192	$4
Metoprolol	40	$187	$5
Pantoprazole	22	$187	$8
Zolpidem	40	$162	$4
Hydromorphone	15	$151	$10
Escitalopram	13	$141	$11
Alendronate	22	$119	$5
Tramadol	19	$118	$6
Cephalexin	12	$92	$8
Atenolol	25	$87	$3
Levetiracetam	12	$85	$7
Trazodone	12	$85	$7
Hydrocodone-Acetaminophen	11	$78	$7
Lorazepam	12	$59	$5

2019: 46 drugs

Sort by

Part D drugs prescribed in 2019

Renvela	40	$64,955	$1,624
Eliquis	17	$14,125	$831
Sevelamer Carbonate	34	$12,467	$367
Lanthanum Carbonate	12	$10,497	$875
Cinacalcet	13	$8,743	$673
Mycophenolic Acid	15	$8,669	$578
Januvia	13	$5,896	$454
Tacrolimus	31	$3,668	$118
Mycophenolate Mofetil	23	$3,114	$135
Calcium Acetate	29	$2,277	$79
Calcitriol	30	$1,594	$53
Diphenhydramine	33	$1,240	$38
Colcrys	11	$1,159	$105
Amlodipine Besylate	145	$979	$7
Chlorthalidone	33	$967	$29
Azathioprine	15	$967	$64
Hydralazine	30	$951	$32
Entecavir	11	$876	$80
Tamsulosin	18	$755	$42
Midodrine	11	$755	$69
Gabapentin	38	$744	$20
Carvedilol	82	$653	$8
Atorvastatin	67	$625	$9
Potassium Chloride	14	$603	$43
Furosemide	62	$572	$9
Allopurinol	42	$553	$13
Zolpidem	52	$527	$10
Labetalol	12	$525	$44
Losartan	44	$495	$11
Lisinopril	65	$479	$7
Pantoprazole	35	$465	$13
Omeprazole	44	$464	$11
Oxycodone-Acetaminophen	11	$414	$38
Prednisone	54	$376	$7
Famotidine	39	$302	$8
Metoprolol	35	$301	$9
Simvastatin	21	$235	$11
Pravastatin	17	$198	$12
Trazodone	28	$149	$5
Alprazolam	16	$116	$7
Atenolol	26	$112	$4
Escitalopram	14	$108	$8
Alendronate	20	$91	$5
Tramadol	23	$89	$4
Ranitidine	11	$66	$6
Amoxicillin	12	$63	$5

2018: 48 drugs

Sort by

Part D drugs prescribed in 2018

Renvela	38	$68,413	$1,800
Sensipar	17	$19,429	$1,143
Voriconazole	12	$13,644	$1,137
Eliquis	20	$12,648	$632
Januvia	12	$5,217	$435
Entecavir	12	$4,347	$362
Mycophenolate Mofetil	23	$2,463	$107
Fentanyl	14	$2,220	$159
Tacrolimus	25	$2,042	$82
Calcium Acetate	26	$1,951	$75
Lidocaine	15	$1,318	$88
Calcitriol	35	$1,241	$35
Allopurinol	55	$999	$18
Oxycodone-Acetaminophen	14	$916	$65
Labetalol	23	$868	$38
Atorvastatin	55	$816	$15
Tamsulosin	24	$809	$34
Hydralazine	26	$792	$30
Azathioprine	11	$782	$71
Gabapentin	32	$769	$24
Ventolin Hfa	14	$767	$55
Eplerenone	11	$742	$67
Amlodipine Besylate	126	$738	$6
Furosemide	64	$679	$11
Losartan	54	$598	$11
Valsartan	16	$558	$35
Midodrine	13	$549	$42
Quinapril	16	$470	$29
Lisinopril	77	$468	$6
Prednisone	57	$450	$8
Zolpidem	56	$444	$8
Levothyroxine	19	$421	$22
Metoprolol	54	$403	$7
Simvastatin	28	$338	$12
Omeprazole	26	$326	$13
Pantoprazole	35	$309	$9
Carvedilol	55	$304	$6
Pravastatin	26	$221	$8
Alendronate	26	$126	$5
Ondansetron	11	$100	$9
Tramadol	20	$96	$5
Trazodone	22	$96	$4
Clopidogrel	15	$81	$5
Famotidine	26	$79	$3
Atenolol	20	$78	$4
Alprazolam	12	$66	$5
Sulfamethoxazole-Trimethoprim	13	$60	$5
Amoxicillin	11	$38	$3

2017: 53 drugs

Sort by

Part D drugs prescribed in 2017

Sensipar	69	$146,255	$2,120
Renvela	40	$74,233	$1,856
Januvia	12	$4,784	$399
Eliquis	12	$4,746	$396
Midodrine	19	$4,117	$217
Entecavir	11	$3,908	$355
Mycophenolate Mofetil	33	$3,451	$105
Calcium Acetate	38	$2,795	$74
Tacrolimus	42	$2,629	$63
Potassium Chloride	13	$1,587	$122
Nitrofurantoin	13	$1,079	$83
Atorvastatin	69	$1,021	$15
Chlorthalidone	19	$939	$49
Metoprolol	25	$933	$37
Eplerenone	12	$909	$76
Nitrofurantoin Mono-Macro	12	$853	$71
Gabapentin	32	$800	$25
Oxycodone-Acetaminophen	14	$798	$57
Valsartan	22	$742	$34
Quinapril	18	$723	$40
Allopurinol	49	$641	$13
Hydralazine	15	$631	$42
Amlodipine Besylate	99	$622	$6
Ventolin Hfa	11	$590	$54
Prednisone	63	$535	$8
Furosemide	97	$522	$5
Lisinopril	69	$506	$7
Levothyroxine	24	$505	$21
Losartan	67	$449	$7
Zolpidem	46	$434	$9
Diltiazem 24hr Er	13	$432	$33
Metoprolol	65	$427	$7
Omeprazole	41	$386	$9
Tamsulosin	18	$373	$21
Pravastatin	30	$362	$12
Carvedilol	64	$341	$5
Simvastatin	45	$341	$8
Calcitriol	22	$336	$15
Fludrocortisone Acetate	13	$313	$24
Nifedipine Er	12	$226	$19
Metformin	12	$207	$17
Ondansetron	15	$204	$14
Pantoprazole	24	$195	$8
Sulfamethoxazole-Trimethoprim	18	$157	$9
Trazodone	21	$127	$6
Clopidogrel	24	$125	$5
Alendronate	22	$97	$4
Cephalexin	15	$74	$5
Atenolol	17	$74	$4
Famotidine	19	$72	$4
Glipizide	14	$59	$4
Escitalopram	14	$57	$4
Alprazolam	12	$40	$3

2016: 52 drugs

Sort by

Part D drugs prescribed in 2016

Sensipar	82	$171,496	$2,091
Renvela	44	$97,432	$2,214
Fosrenol	17	$16,731	$984
Januvia	11	$4,072	$370
Tacrolimus	45	$3,821	$85
Calcium Acetate	49	$3,631	$74
Clinisol	26	$2,461	$95
Metoprolol	58	$2,195	$38
Atorvastatin	75	$1,746	$23
Chlorthalidone	18	$1,494	$83
Nitrofurantoin	17	$1,078	$63
Valsartan	23	$998	$43
Mycophenolate Mofetil	29	$996	$34
Hydralazine	29	$943	$33
Losartan	82	$923	$11
Isosorbide Dinitrate	12	$891	$74
Amlodipine Besylate	123	$864	$7
Allopurinol	42	$805	$19
Pravastatin	35	$796	$23
Azathioprine	24	$790	$33
Nitrofurantoin Mono-Macro	13	$766	$59
Nifedipine Er	19	$714	$38
Omeprazole	60	$700	$12
Furosemide	133	$609	$5
Quinapril	19	$585	$31
Lisinopril	81	$541	$7
Potassium Chloride	17	$501	$29
Gabapentin	35	$496	$14
Metoprolol	69	$493	$7
Prednisone	66	$458	$7
Zolpidem	45	$415	$9
Simvastatin	50	$411	$8
Carvedilol	58	$320	$6
Levothyroxine	21	$320	$15
Tamsulosin	16	$306	$19
Pantoprazole	25	$285	$11
Oxcarbazepine	11	$252	$23
Calcitriol	20	$249	$12
Cephalexin	20	$249	$12
Paroxetine	17	$210	$12
Clopidogrel	40	$208	$5
Clonidine	11	$201	$18
Sulfamethoxazole-Trimethoprim	17	$187	$11
Trazodone	29	$178	$6
Alendronate	31	$139	$4
Glipizide	21	$130	$6
Loperamide	11	$109	$10
Digoxin	13	$97	$7
Atenolol	20	$86	$4
Famotidine	28	$79	$3
Metformin	15	$72	$5
Diazepam	12	$41	$3

2015: 53 drugs

Sort by

Part D drugs prescribed in 2015

Renvela	68	$123,830	$1,821
Sensipar	91	$115,472	$1,269
Clinisol	57	$7,842	$138
Midodrine	12	$6,569	$547
Tacrolimus	54	$5,724	$106
Januvia	12	$4,658	$388
Calcium Acetate	36	$3,731	$104
Cyclosporine Modified	12	$2,488	$207
Valsartan	17	$2,056	$121
Metoprolol	51	$1,988	$39
Atorvastatin	76	$1,543	$20
Potassium Chloride	19	$1,454	$77
Mycophenolate Mofetil	37	$1,258	$34
Amlodipine Besylate	168	$1,195	$7
Isosorbide Dinitrate	16	$1,167	$73
Calcitriol	68	$972	$14
Nifedipine Er	24	$966	$40
Losartan	77	$899	$12
Hydralazine	39	$876	$22
Azathioprine	20	$863	$43
Pravastatin	32	$848	$27
Nitrofurantoin	17	$828	$49
Prednisone	90	$681	$8
Quinapril	25	$662	$26
Furosemide	149	$662	$4
Allopurinol	57	$620	$11
Gabapentin	37	$593	$16
Omeprazole	63	$545	$9
Tamsulosin	14	$481	$34
Simvastatin	65	$468	$7
Pantoprazole	45	$467	$10
Lisinopril	76	$438	$6
Metoprolol	78	$429	$5
Levothyroxine	20	$361	$18
Carvedilol	63	$319	$5
Oxcarbazepine	12	$275	$23
Paroxetine	17	$264	$16
Clonidine	24	$241	$10
Zolpidem	35	$204	$6
Clopidogrel	37	$194	$5
Hydrocodone-Acetaminophen	12	$191	$16
Amitriptyline	12	$154	$13
Loperamide	13	$152	$12
Tramadol	11	$137	$12
Ciprofloxacin	11	$127	$12
Trazodone	25	$125	$5
Alendronate	19	$107	$6
Atenolol	12	$89	$7
Hydrochlorothiazide	11	$72	$7
Cephalexin	11	$67	$6
Glipizide	15	$66	$4
Diazepam	13	$55	$4
Famotidine	13	$21	$2

2014: 54 drugs

Sort by

Part D drugs prescribed in 2014

Sensipar	74	$82,229	$1,111
Renvela	81	$81,515	$1,006
Sevelamer Carbonate	19	$17,054	$898
Tacrolimus	53	$10,519	$198
Clinisol	67	$10,079	$150
Diovan	15	$5,042	$336
Januvia	12	$4,678	$390
Calcium Acetate	36	$3,468	$96
Metoprolol	78	$3,113	$40
Novolin R	15	$1,704	$114
Generlac	18	$1,414	$79
Potassium Chloride	13	$1,338	$103
Calcitriol	56	$1,292	$23
Atorvastatin	62	$1,257	$20
Isosorbide Dinitrate	12	$1,181	$98
Amlodipine Besylate	144	$1,121	$8
Nifedical Xl	19	$1,092	$57
Mycophenolate Mofetil	20	$989	$49
Potassium Citrate Er	13	$871	$67
Tamsulosin	28	$821	$29
Nitrofurantoin	13	$806	$62
Quinapril	22	$755	$34
Furosemide	134	$747	$6
Diltiazem 24hr Er	14	$739	$53
Simvastatin	71	$737	$10
Hydralazine	35	$728	$21
Losartan	84	$707	$8
Nitrofurantoin Mono-Macro	12	$622	$52
Azathioprine	30	$612	$20
Gabapentin	28	$554	$20
Lisinopril	84	$543	$6
Metoprolol	75	$405	$5
Prednisone	52	$403	$8
Omeprazole	32	$367	$11
Hydrocodone-Acetaminophen	39	$324	$8
Carvedilol	38	$317	$8
Allopurinol	58	$310	$5
Clonidine	34	$294	$9
Oxcarbazepine	12	$275	$23
Pantoprazole	31	$271	$9
Levothyroxine	12	$257	$21
Amitriptyline	14	$213	$15
Ciprofloxacin	11	$191	$17
Paroxetine	14	$150	$11
Clopidogrel	19	$142	$7
Lovastatin	16	$131	$8
Alendronate	16	$129	$8
Megestrol Acetate	12	$122	$10
Glipizide	20	$122	$6
Torsemide	15	$120	$8
Warfarin	14	$90	$6
Sulfamethoxazole-Trimethoprim	14	$76	$5
Clonazepam	14	$50	$4
Diazepam	12	$36	$3

2013: 62 drugs

Sort by

Part D drugs prescribed in 2013

Renvela	105	$75,917	$723
Sensipar	84	$62,784	$747
Tacrolimus	34	$8,871	$261
Clinisol	51	$7,923	$155
Lunesta	14	$7,091	$507
Calcium Acetate	44	$6,325	$144
Procardia Xl	11	$3,094	$281
Metoprolol	83	$3,040	$37
Januvia	11	$2,989	$272
Atorvastatin	64	$2,316	$36
Colcrys	14	$2,177	$156
Lantus	12	$1,898	$158
Amlodipine Besylate	168	$1,673	$10
Novolin R	19	$1,592	$84
Calcitriol	60	$1,513	$25
Potassium Chloride	16	$1,503	$94
Mycophenolate Mofetil	17	$1,480	$87
Generlac	17	$1,301	$77
Diltiazem 24hr Er	29	$1,245	$43
Furosemide	190	$1,127	$6
Clonidine	13	$1,109	$85
Quinapril	28	$1,005	$36
Losartan	79	$899	$11
Nifedical Xl	18	$894	$50
Potassium Citrate	11	$874	$79
Nitrofurantoin	12	$772	$64
Omeprazole	63	$740	$12
Clopidogrel	16	$709	$44
Nifedipine Er	12	$688	$57
Voltaren	15	$658	$44
Simvastatin	57	$651	$11
Gabapentin	36	$643	$18
Lisinopril	87	$637	$7
Proair Hfa	11	$519	$47
Metoprolol	51	$452	$9
Prednisone	57	$410	$7
Allopurinol	60	$402	$7
Hydralazine	20	$398	$20
Hydrocodone-Acetaminophen	34	$390	$11
Clonidine	47	$367	$8
Tamsulosin	17	$363	$21
Pravastatin	18	$354	$20
Azathioprine	18	$346	$19
Paroxetine	18	$309	$17
Insulin	13	$306	$24
Pioglitazone	13	$299	$23
Pantoprazole	28	$298	$11
Carvedilol	29	$278	$10
Zolpidem	29	$192	$7
Ciprofloxacin	20	$167	$8
Metoclopramide	19	$158	$8
Lovastatin	16	$153	$10
Benazepril	30	$138	$5
Levetiracetam	14	$122	$9
Warfarin	12	$114	$10
Sulfamethoxazole-Trimethoprim	18	$113	$6
Megestrol Acetate	12	$110	$9
Levothyroxine	13	$92	$7
Metformin Hcl Er	12	$66	$5
Lorazepam	11	$59	$5
Amitriptyline	11	$48	$4
Diazepam	12	$41	$3

Money from drug and device companies

$97,844 in 2025

Sort by

Industry payments by year

2025	8	80	$91,087	$97,844
2024	8	93	$138,093	$163,484
2023	12	65	$56,900	$96,848
2022	7	29	$37,100	$39,806
2021	6	17	$19,940	$27,637
2020	6	22	$30,400	$32,754
2019	4	13	$5,500	$8,871

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Novartis Pharmaceuticals	Fabhalta	$30,404	20 payments Meals for Vanrafia · 2025-11-06 · $55 Meals for Vanrafia · 2025-09-24 · $44 Meals · 2025-08-14 · $6 Consulting · 2025-06-12 · $375 Consulting · 2025-06-11 · $750 Meals for Vanrafia · 2025-04-19 · $16 Meals for Vanrafia · 2025-04-18 · $18 Meals · 2025-04-18 · $32 Consulting · 2025-04-18 · $3,150 Meals for Fabhalta · 2025-04-14 · $44 Consulting for Fabhalta · 2025-04-14 · $3,150 Consulting · 2025-03-31 · $4,125 Consulting for Fabhalta · 2025-03-21 · $3,000 Meals · 2025-03-20 · $25 Meals for Vanrafia · 2025-03-05 · $66 Meals · 2025-02-28 · $225 Consulting · 2025-02-28 · $14,350 Travel · 2025-02-28 · $251 Travel · 2025-02-28 · $90 Travel for Fabhalta · 2025-02-27 · $632
Alexion Pharmaceuticals	None	$20,055	17 payments Consulting · 2025-12-12 · $1,340 Meals · 2025-11-06 · $99 Consulting · 2025-11-05 · $2,680 Consulting · 2025-10-01 · $8,710 Consulting · 2025-07-14 · $670 Consulting · 2025-06-26 · $1,340 Consulting · 2025-06-25 · $335 Travel · 2025-06-17 · $405 Meals · 2025-06-17 · $54 Meals · 2025-06-17 · $70 Meals · 2025-06-17 · $135 Travel · 2025-06-17 · $331 Meals · 2025-06-17 · $55 Meals · 2025-06-17 · $55 Travel · 2025-05-14 · $552 Consulting · 2025-04-10 · $3,183 Meals · 2025-04-10 · $41
Otsuka Pharmaceutical Development & Commercialization	None	$19,477	16 payments Consulting · 2025-12-22 · $2,008 Meals · 2025-09-23 · $44 Consulting · 2025-07-24 · $2,190 Consulting · 2025-07-24 · $730 Consulting · 2025-06-16 · $2,555 Meals · 2025-06-07 · $53 Meals · 2025-04-12 · $21 Consulting · 2025-03-26 · $2,555 Consulting · 2025-03-13 · $1,825 Consulting · 2025-03-06 · $6,132 Meals · 2025-03-06 · $33 Travel · 2025-03-06 · $35 Meals · 2025-03-06 · $44 Travel · 2025-03-06 · $673 Travel · 2025-03-06 · $32 Consulting · 2025-01-03 · $548
Vertex Pharmaceuticals	Journavx	$17,144	17 payments Consulting · 2025-12-17 · $3,185 Travel for Journavx · 2025-11-09 · $333 Meals · 2025-11-08 · $73 Consulting for Journavx · 2025-11-08 · $2,958 Meals · 2025-11-05 · $84 Travel · 2025-06-11 · $834 Consulting · 2025-06-11 · $9,000 Travel · 2025-06-11 · $22 Travel · 2025-06-11 · $54 Meals · 2025-06-05 · $41 Meals · 2025-04-08 · $29 Meals · 2025-04-08 · $20 Travel · 2025-04-08 · $348 Meals · 2025-04-08 · $25 Travel · 2025-04-08 · $68 Meals · 2025-01-29 · $43 Meals · 2025-01-29 · $29
Calliditas Therapeutics US	Tarpeyo	$9,095	5 payments Consulting for Tarpeyo · 2025-12-11 · $575 Consulting for Tarpeyo · 2025-06-11 · $2,065 Meals for Tarpeyo · 2025-04-09 · $130 Consulting for Tarpeyo · 2025-03-24 · $2,300 Consulting for Tarpeyo · 2025-02-13 · $4,025
Takeda Pharmaceuticals U.S.A.	None	$1,280	2 payments Consulting · 2025-04-02 · $640 Consulting · 2025-02-14 · $640

See all 80 published payments

Sort by

Every published payment

Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-12-22	None	$2,008
Vertex Pharmaceuticals	Consulting · 2025-12-17	None	$3,185
Alexion Pharmaceuticals	Consulting · 2025-12-12	None	$1,340
Calliditas Therapeutics US	Consulting · 2025-12-11	Tarpeyo	$575
Vertex Pharmaceuticals	Travel · 2025-11-09	Journavx	$333
Vertex Pharmaceuticals	Meals · 2025-11-08	None	$73
Vertex Pharmaceuticals	Consulting · 2025-11-08	Journavx	$2,958
Novartis Pharmaceuticals	Meals · 2025-11-06	Vanrafia	$55
Alexion Pharmaceuticals	Meals · 2025-11-06	None	$99
Mallinckrodt Hospital Products	Meals · 2025-11-06	Acthar	$88
Alexion Pharmaceuticals	Consulting · 2025-11-05	None	$2,680
Vertex Pharmaceuticals	Meals · 2025-11-05	None	$84
Apellis Pharmaceuticals	Meals · 2025-11-04	Empaveli	$162
Alexion Pharmaceuticals	Consulting · 2025-10-01	None	$8,710
Novartis Pharmaceuticals	Meals · 2025-09-24	Vanrafia	$44
Otsuka Pharmaceutical Development & Commercialization	Meals · 2025-09-23	None	$44
Apellis Pharmaceuticals	Meals · 2025-09-06	None	$139
Novartis Pharmaceuticals	Meals · 2025-08-14	None	$6
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-07-24	None	$2,190
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-07-24	None	$730
Alexion Pharmaceuticals	Consulting · 2025-07-14	None	$670
Alexion Pharmaceuticals	Consulting · 2025-06-26	None	$1,340
Alexion Pharmaceuticals	Consulting · 2025-06-25	None	$335
Alexion Pharmaceuticals	Travel · 2025-06-17	None	$405
Alexion Pharmaceuticals	Meals · 2025-06-17	None	$54
Alexion Pharmaceuticals	Meals · 2025-06-17	None	$70
Alexion Pharmaceuticals	Meals · 2025-06-17	None	$135
Alexion Pharmaceuticals	Travel · 2025-06-17	None	$331
Alexion Pharmaceuticals	Meals · 2025-06-17	None	$55
Alexion Pharmaceuticals	Meals · 2025-06-17	None	$55
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-06-16	None	$2,555
Novartis Pharmaceuticals	Consulting · 2025-06-12	None	$375
Novartis Pharmaceuticals	Consulting · 2025-06-11	None	$750
Vertex Pharmaceuticals	Travel · 2025-06-11	None	$834
Vertex Pharmaceuticals	Consulting · 2025-06-11	None	$9,000
Vertex Pharmaceuticals	Travel · 2025-06-11	None	$22
Vertex Pharmaceuticals	Travel · 2025-06-11	None	$54
Calliditas Therapeutics US	Consulting · 2025-06-11	Tarpeyo	$2,065
Otsuka Pharmaceutical Development & Commercialization	Meals · 2025-06-07	None	$53
Vertex Pharmaceuticals	Meals · 2025-06-05	None	$41
Alexion Pharmaceuticals	Travel · 2025-05-14	None	$552
Novartis Pharmaceuticals	Meals · 2025-04-19	Vanrafia	$16
Novartis Pharmaceuticals	Meals · 2025-04-18	Vanrafia	$18
Novartis Pharmaceuticals	Meals · 2025-04-18	None	$32
Novartis Pharmaceuticals	Consulting · 2025-04-18	None	$3,150
Novartis Pharmaceuticals	Meals · 2025-04-14	Fabhalta	$44
Novartis Pharmaceuticals	Consulting · 2025-04-14	Fabhalta	$3,150
Otsuka Pharmaceutical Development & Commercialization	Meals · 2025-04-12	None	$21
Alexion Pharmaceuticals	Consulting · 2025-04-10	None	$3,183
Alexion Pharmaceuticals	Meals · 2025-04-10	None	$41
Calliditas Therapeutics US	Meals · 2025-04-09	Tarpeyo	$130
Vertex Pharmaceuticals	Meals · 2025-04-08	None	$29
Vertex Pharmaceuticals	Meals · 2025-04-08	None	$20
Vertex Pharmaceuticals	Travel · 2025-04-08	None	$348
Vertex Pharmaceuticals	Meals · 2025-04-08	None	$25
Vertex Pharmaceuticals	Travel · 2025-04-08	None	$68
Takeda Pharmaceuticals U.S.A.	Consulting · 2025-04-02	None	$640
Novartis Pharmaceuticals	Consulting · 2025-03-31	None	$4,125
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-03-26	None	$2,555
Calliditas Therapeutics US	Consulting · 2025-03-24	Tarpeyo	$2,300
Novartis Pharmaceuticals	Consulting · 2025-03-21	Fabhalta	$3,000
Novartis Pharmaceuticals	Meals · 2025-03-20	None	$25
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-03-13	None	$1,825
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-03-06	None	$6,132
Otsuka Pharmaceutical Development & Commercialization	Meals · 2025-03-06	None	$33
Otsuka Pharmaceutical Development & Commercialization	Travel · 2025-03-06	None	$35
Otsuka Pharmaceutical Development & Commercialization	Meals · 2025-03-06	None	$44
Otsuka Pharmaceutical Development & Commercialization	Travel · 2025-03-06	None	$673
Otsuka Pharmaceutical Development & Commercialization	Travel · 2025-03-06	None	$32
Novartis Pharmaceuticals	Meals · 2025-03-05	Vanrafia	$66
Novartis Pharmaceuticals	Meals · 2025-02-28	None	$225
Novartis Pharmaceuticals	Consulting · 2025-02-28	None	$14,350
Novartis Pharmaceuticals	Travel · 2025-02-28	None	$251
Novartis Pharmaceuticals	Travel · 2025-02-28	None	$90
Novartis Pharmaceuticals	Travel · 2025-02-27	Fabhalta	$632
Takeda Pharmaceuticals U.S.A.	Consulting · 2025-02-14	None	$640
Calliditas Therapeutics US	Consulting · 2025-02-13	Tarpeyo	$4,025
Vertex Pharmaceuticals	Meals · 2025-01-29	None	$43
Vertex Pharmaceuticals	Meals · 2025-01-29	None	$29
Otsuka Pharmaceutical Development & Commercialization	Consulting · 2025-01-03	None	$548

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $163,484

Sort by

Payments by company in 2024

Alexion Pharmaceuticals	Ultomiris	$62,320	32 payments Consulting · 2024-12-09 · $3,350 Consulting · 2024-11-14 · $13,735 Travel · 2024-09-19 · $197 Meals · 2024-09-19 · $135 Meals · 2024-09-19 · $40 Meals · 2024-09-19 · $60 Meals · 2024-09-19 · $50 Travel · 2024-09-19 · $197 Meals · 2024-09-19 · $50 Meals · 2024-09-19 · $135 Meals · 2024-09-19 · $40 Travel · 2024-09-19 · $204 Meals · 2024-09-19 · $40 Meals · 2024-09-19 · $60 Travel · 2024-08-26 · $650 Consulting · 2024-07-24 · $1,340 Consulting · 2024-07-24 · $1,675 Consulting · 2024-07-24 · $670 Consulting · 2024-06-10 · $26,800 Meals for Ultomiris · 2024-05-03 · $154 Meals for Ultomiris · 2024-05-02 · $25 Meals for Ultomiris · 2024-05-02 · $86 Meals for Ultomiris · 2024-05-01 · $49 Meals for Ultomiris · 2024-05-01 · $33 Meals for Ultomiris · 2024-04-30 · $34 Meals for Ultomiris · 2024-04-30 · $50 Travel for Ultomiris · 2024-04-29 · $155 Meals for Ultomiris · 2024-04-29 · $63 Travel for Ultomiris · 2024-04-29 · $1,347 Travel for Ultomiris · 2024-04-28 · $8,886 Consulting · 2024-03-02 · $1,340 Consulting · 2024-03-01 · $670
Calliditas Therapeutics US	Tarpeyo	$36,727	21 payments Travel for Tarpeyo · 2024-12-18 · $327 Travel for Tarpeyo · 2024-11-06 · $646 Travel for Tarpeyo · 2024-11-06 · $1,487 Consulting for Tarpeyo · 2024-10-21 · $3,450 Consulting for Tarpeyo · 2024-10-01 · $6,325 Travel for Tarpeyo · 2024-10-01 · $52 Travel for Tarpeyo · 2024-09-27 · $928 Meals for Tarpeyo · 2024-09-27 · $360 Meals for Tarpeyo · 2024-09-27 · $117 Consulting for Tarpeyo · 2024-08-26 · $5,175 Consulting for Tarpeyo · 2024-06-06 · $1,150 Consulting for Tarpeyo · 2024-06-06 · $3,450 Consulting for Tarpeyo · 2024-06-06 · $2,300 Travel for Tarpeyo · 2024-06-06 · $1,358 Consulting for Tarpeyo · 2024-05-13 · $1,150 Consulting for Tarpeyo · 2024-05-09 · $1,438 Travel for Tarpeyo · 2024-05-09 · $395 Meals for Tarpeyo · 2024-04-13 · $65 Consulting for Tarpeyo · 2024-01-29 · $3,850 Travel for Tarpeyo · 2024-01-29 · $2,584 Meals for Tarpeyo · 2024-01-18 · $119
Novartis Pharmaceuticals	None	$32,558	21 payments Consulting · 2024-12-09 · $325 Consulting · 2024-10-11 · $2,600 Meals · 2024-09-14 · $132 Travel · 2024-09-06 · $295 Consulting · 2024-09-06 · $7,200 Meals · 2024-09-06 · $175 Travel · 2024-09-06 · $755 Meals · 2024-09-05 · $139 Consulting · 2024-06-14 · $5,200 Meals · 2024-05-25 · $60 Meals · 2024-04-15 · $11 Consulting · 2024-02-10 · $4,875 Travel · 2024-02-10 · $432 Meals · 2024-02-10 · $225 Consulting · 2024-02-09 · $8,500 Travel · 2024-02-09 · $216 Travel · 2024-02-09 · $369 Meals · 2024-02-09 · $210 Meals · 2024-02-09 · $140 Travel · 2024-02-08 · $694 Meals · 2024-02-07 · $5
Otsuka Pharmaceutical Development & Commercialization	None	$10,220	3 payments Consulting · 2024-12-03 · $365 Consulting · 2024-10-24 · $3,285 Consulting · 2024-07-22 · $6,570
Travere Therapeutics	None	$9,679	4 payments Meals · 2024-10-22 · $106 Meals · 2024-05-24 · $73 Paid to speak or teach · 2024-05-07 · $1,500 Paid to speak or teach · 2024-02-27 · $8,000
Otsuka America Pharmaceutical	None	$4,525	2 payments Consulting · 2024-12-09 · $4,380 Meals · 2024-10-24 · $145
Vertex Pharmaceuticals	None	$3,954	3 payments Consulting · 2024-11-27 · $3,375 Meals · 2024-10-24 · $29 Consulting · 2024-03-06 · $550
Biogen	None	$3,500	2 payments Consulting · 2024-12-10 · $3,000 Consulting · 2024-07-08 · $500

2023: $96,848

Sort by

Payments by company in 2023

BioCryst Pharmaceuticals	None	$32,732	16 payments Consulting · 2023-12-22 · $2,548 Consulting · 2023-11-10 · $1,911 Meals · 2023-09-30 · $107 Consulting · 2023-09-15 · $4,778 Travel · 2023-09-15 · $6,689 Travel · 2023-09-15 · $93 Travel · 2023-07-30 · $186 Meals · 2023-07-29 · $90 Meals · 2023-07-29 · $86 Travel · 2023-07-29 · $396 Travel · 2023-07-29 · $113 Travel · 2023-07-29 · $225 Meals · 2023-07-28 · $51 Travel · 2023-07-28 · $394 Travel · 2023-07-28 · $227 Travel · 2023-07-13 · $14,839
GlaxoSmithKline	Benlysta	$18,380	2 payments Consulting for Benlysta · 2023-04-18 · $1,300 Consulting · 2023-01-30 · $17,080
Calliditas Therapeutics US	Tarpeyo	$18,076	6 payments Consulting for Tarpeyo · 2023-11-01 · $3,225 Travel for Tarpeyo · 2023-10-31 · $67 Travel for Tarpeyo · 2023-09-26 · $10,209 Consulting for Tarpeyo · 2023-09-26 · $3,000 Consulting for Tarpeyo · 2023-02-02 · $1,050 Consulting for Tarpeyo · 2023-01-13 · $525
Travere Therapeutics	None	$8,310	16 payments Travel · 2023-12-13 · $930 Travel · 2023-12-13 · $102 Travel · 2023-12-12 · $930 Paid to speak or teach · 2023-12-12 · $4,000 Travel · 2023-12-12 · $102 Meals · 2023-10-27 · $20 Meals · 2023-10-27 · $72 Meals · 2023-10-21 · $40 Meals · 2023-10-21 · $50 Meals · 2023-10-21 · $75 Travel · 2023-10-21 · $169 Travel · 2023-10-20 · $201 Travel · 2023-10-20 · $441 Meals · 2023-10-20 · $23 Meals · 2023-10-20 · $156 Paid to speak or teach · 2023-08-29 · $1,000
BeiGene USA	Brukinsa	$7,180	12 payments Consulting for Brukinsa · 2023-10-04 · $5,500 Travel for Brukinsa · 2023-05-18 · $15 Travel for Brukinsa · 2023-05-18 · $23 Travel for Brukinsa · 2023-05-18 · $36 Travel for Brukinsa · 2023-05-18 · $72 Meals for Brukinsa · 2023-05-06 · $74 Meals for Brukinsa · 2023-05-06 · $93 Meals for Brukinsa · 2023-05-06 · $109 Travel for Brukinsa · 2023-05-06 · $256 Travel for Brukinsa · 2023-05-06 · $373 Travel for Brukinsa · 2023-05-06 · $434 Meals for Brukinsa · 2023-05-05 · $195
ANI Pharmaceuticals	Purified Cortrophin Gel	$5,077	4 payments Honoraria for Purified Cortrophin Gel · 2023-03-23 · $4,275 Travel for Purified Cortrophin Gel · 2023-03-23 · $115 Meals for Purified Cortrophin Gel · 2023-02-13 · $76 Travel for Purified Cortrophin Gel · 2023-02-12 · $611
Pfizer	None	$3,250	1 payment Consulting · 2023-01-16 · $3,250
Chugai Pharmaceutical Co.	None	$1,830	1 payment Consulting · 2023-09-15 · $1,830
Novartis Pharmaceuticals	None	$1,636	3 payments Meals · 2023-08-22 · $5 Meals · 2023-06-28 · $7 Consulting · 2023-06-27 · $1,625
Otsuka Pharmaceutical Development & Commercialization	None	$198	2 payments Paid to speak or teach · 2023-10-30 · $4 Meals · 2023-06-15 · $195
Alexion Pharmaceuticals	Ultomiris	$100	1 payment Meals for Ultomiris · 2023-11-27 · $100
Amgen	Aranesp	$79	1 payment Meals for Aranesp · 2023-05-08 · $79

2022: $39,806

Sort by

Payments by company in 2022

Calliditas Therapeutics US	Tarpeyo	$17,850	7 payments Consulting for Tarpeyo · 2022-11-05 · $2,625 Consulting for Tarpeyo · 2022-10-28 · $525 Consulting for Tarpeyo · 2022-10-25 · $525 Consulting for Tarpeyo · 2022-10-24 · $525 Consulting for Tarpeyo · 2022-08-11 · $3,150 Honoraria for Tarpeyo · 2022-04-06 · $5,250 Consulting for Tarpeyo · 2022-04-06 · $5,250
Travere Therapeutics	None	$8,957	9 payments Consulting · 2022-12-08 · $3,500 Meals · 2022-11-04 · $27 Travel · 2022-10-18 · $426 Consulting · 2022-09-06 · $4,400 Meals · 2022-08-27 · $41 Meals · 2022-08-27 · $54 Meals · 2022-08-27 · $73 Meals · 2022-08-26 · $129 Travel · 2022-08-26 · $306
Amgen	Tavneos	$6,274	6 payments Honoraria for Tavneos · 2022-12-07 · $4,800 Travel for Tavneos · 2022-12-07 · $1,007 Meals for Tavneos · 2022-10-14 · $78 Meals for Tavneos · 2022-10-08 · $80 Meals for Tavneos · 2022-10-08 · $89 Meals for Tavneos · 2022-10-08 · $220
Novartis Pharmaceuticals	None	$4,614	2 payments Meals · 2022-05-20 · $64 Consulting · 2022-03-09 · $4,550
Aurinia Pharma U.S.	Lupkynis	$2,073	3 payments Meals for Lupkynis · 2022-07-13 · $23 Meals for Lupkynis · 2022-02-12 · $50 Honoraria for Lupkynis · 2022-02-12 · $2,000
Alnylam Pharmaceuticals	None	$24	1 payment Meals · 2022-11-05 · $24
Alexion Pharmaceuticals	Ultomiris	$14	1 payment Meals for Ultomiris · 2022-04-07 · $14

2021: $27,637

Sort by

Payments by company in 2021

Travere Therapeutics	None	$9,583	7 payments Consulting · 2021-09-21 · $2,000 Consulting · 2021-07-07 · $1,500 Education · 2021-05-07 · $1,800 Consulting · 2021-05-07 · $1,800 Consulting · 2021-04-19 · $400 Consulting · 2021-02-18 · $2,000 Meals · 2021-01-13 · $83
Omeros	None	$4,944	1 payment Education · 2021-04-01 · $4,944
Aurinia Pharma U.S.	Lupkynis	$4,891	6 payments Meals for Lupkynis · 2021-10-09 · $141 Travel for Lupkynis · 2021-10-09 · $194 Travel for Lupkynis · 2021-10-09 · $329 Honoraria for Lupkynis · 2021-10-09 · $4,020 Travel for Lupkynis · 2021-10-09 · $185 Meals for Lupkynis · 2021-10-09 · $23
Alexion Pharmaceuticals	None	$4,240	1 payment Consulting · 2021-04-07 · $4,240
Otsuka Pharmaceutical Development & Commercialization	None	$3,400	1 payment Consulting · 2021-07-07 · $3,400
Novartis Pharmaceuticals	None	$580	1 payment Consulting · 2021-08-24 · $580

2020: $32,754

Sort by

Payments by company in 2020

Travere Therapeutics	None	$8,169	10 payments Consulting · 2020-11-05 · $4,000 Meals · 2020-09-21 · $70 Consulting · 2020-03-19 · $3,000 Travel · 2020-03-19 · $758 Meals · 2020-02-08 · $47 Meals · 2020-02-08 · $52 Meals · 2020-02-08 · $20 Meals · 2020-02-07 · $1 Travel · 2020-02-07 · $143 Meals · 2020-02-07 · $78
Mallinckrodt Hospital Products	Acthar	$7,935	7 payments Consulting for Acthar · 2020-03-03 · $6,750 Travel for Acthar · 2020-03-03 · $50 Travel for Acthar · 2020-03-03 · $162 Travel for Acthar · 2020-03-02 · $433 Travel for Acthar · 2020-03-02 · $38 Travel for Acthar · 2020-03-02 · $177 Travel for Acthar · 2020-02-11 · $324
Alexion Pharmaceuticals	Ultomiris	$6,620	2 payments Consulting for Ultomiris · 2020-06-29 · $2,120 Consulting for Ultomiris · 2020-04-30 · $4,500
Novartis Pharmaceuticals	None	$4,350	1 payment Consulting · 2020-09-15 · $4,350
GlaxoSmithKline	None	$3,680	1 payment Consulting · 2020-07-02 · $3,680
Amgen	Epogen	$2,000	1 payment Consulting for Epogen · 2020-12-21 · $2,000

2019: $8,871

Sort by

Payments by company in 2019

Otsuka Pharmaceutical Co.	None	$5,080	5 payments Meals · 2019-11-08 · $34 Travel · 2019-05-09 · $796 Consulting · 2019-03-12 · $3,000 Meals · 2019-02-28 · $665 Travel · 2019-01-31 · $585
Retrophin	None	$3,332	2 payments Consulting · 2019-09-05 · $2,500 Travel · 2019-09-05 · $832
Omeros	Omidria	$374	5 payments Meals for Omidria · 2019-11-12 · $2 Meals for Omidria · 2019-10-30 · $51 Meals for Omidria · 2019-06-15 · $46 Meals for Omidria · 2019-06-11 · $211 Meals for Omidria · 2019-06-07 · $63
Pfizer	None	$86	1 payment Meals · 2019-11-07 · $86

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Novartis Pharmaceuticals Corporation · A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases · 2025	Their institution	$509,730
BeiGene, Ltd. · A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-Label Study To Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy · 2024	Their institution	$447,552
BeiGene, Ltd. · A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-Label Study To Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy · 2025	Their institution	$322,612
Novartis Pharmaceuticals Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients With Iga Nephropathy at Risk of Progressive Loss of Renal Function · 2025	Their institution	$247,957
BeOne Medicines Ltd. · A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-Label Study To Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy · 2025	Their institution	$125,480
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 2/3, Multicenter, Open-Label Trial To Evaluate the Long-Term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2024	Their institution	$70,959
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2024	Their institution	$65,355
Travere Therapeutics, Inc. · 021igan17001 · 2024	Their institution	$60,450
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2025	Their institution	$53,275
PFIZER INC. · A Phase 2 12 Week Adaptive Open Label Sequential Cohort Trial To Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of Pf 06730512 Following Multiple Doses in Adult Subjects With Focal Segmental Glomerulosclerosis Fsgs · 2023	Their institution	$51,877
Otsuka Pharmaceutical Co., Ltd. · Phase II of Vis649 for Iga Nephropathy · 2021	Their institution	$43,807
Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2024	This clinician	$34,727
Travere Therapeutics, Inc. · Protect Study in Iga Nephropathy · 2025	Their institution	$34,380
PFIZER INC. · A Phase 2 12 Week Adaptive Open Label Sequential Cohort Trial To Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of Pf 06730512 Following Multiple Doses in Adult Subjects With Focal Segmental Glomerulosclerosis Fsgs · 2022	Their institution	$33,454
Otsuka Pharmaceutical Co., Ltd. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study To Evaluate the Efficacy and Safety of Vis649 in Participants With Immunoglobulin A (Iga) Nephropathy · 2022	Their institution	$33,386
Genentech, Inc. · Randomised Double Blind Study To Evaluate Safety and Efficacy of Obinutuzumab in Class III and IV Ln · 2024	Their institution	$32,908
Travere Therapeutics, Inc. · 021igan17001 · 2021	Their institution	$31,673
Mallinckrodt Enterprises LLC · Two Part Prospective Study of H.P. Acthar Gel in the Treatment of Proteinuria Due To Idiopathis Focal Segmental Glomerulosclerosis Fsgs · 2019	Their institution	$30,909
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2023	Their institution	$29,867
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (Ln) Or Immunoglobulin A Nephropathy (Igan) · 2025	Their institution	$29,423
Travere Therapeutics, Inc. · 021igan17001 · 2020	Their institution	$25,771
Novartis Pharmaceuticals Corporation · A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases · 2024	Their institution	$24,868
Novartis Pharmaceuticals Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients With Iga Nephropathy at Risk of Progressive Loss of Renal Function · 2024	Their institution	$20,389
Retrophin, Inc. · 021igan17001 · 2019	Their institution	$19,713
Novartis Pharmaceuticals Corporation · Impact of Iga Nephropathy on Work, Productivity, and Activity Impairment in the United States: Results From A Real-Wor Ld Study-Amcp · 2023	This clinician	$19,489
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3b, Multi-Center, Open-Label Trial To Evaluate the Long Term Safety of Titrated Immediate-Release Tolvaptan Opc-41061, 30 Mg To 120 Mgday, Split Dose in Subjects With Autosomal Dominant Polycystic Kidney Disease · 2019	Their institution	$18,908
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 2/3, Multicenter, Open-Label Trial To Evaluate the Long-Term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2025	Their institution	$18,281
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (Ln) Or Immunoglobulin A Nephropathy (Igan) · 2022	Their institution	$17,814
Travere Therapeutics, Inc. · 021igan17001 · 2023	Their institution	$17,001
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2022	This clinician	$16,750
Genentech, Inc. · Randomised Double Blind Study To Evaluate Safety and Efficacy of Obinutuzumab in Class III and IV Ln · 2021	Their institution	$15,968
Alexion Pharmaceuticals, Inc. · A Phase 3,Randomized,Double Blind,Placebo Controlled Study To Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy Igan · 2025	Their institution	$14,868
Novartis Pharmaceuticals Corporation · Clnp023a2004 · 2025	This clinician	$14,344
BIOVERATIV THERAPEUTICS INC. · Pd-Rg012-06-Target Population-Alport Syndrome-Renal Bx · 2020	Their institution	$12,101
Apellis Pharmaceuticals, Inc. · Phase II Study Assessing Safety and Efficacy of Apl-2 in Glomerulopathies · 2024	Their institution	$11,982
PFIZER INC. · Robo2 Esoe · 2019	Their institution	$10,957
Genentech, Inc. · Randomised Double Blind Study To Evaluate Safety and Efficacy of Obinutuzumab in Class III and IV Ln · 2025	Their institution	$9,887
Amgen Inc. · Ph2 Avacopan in Adult and Adolescent 12-17 Subjects With C3g · 2024	Their institution	$9,805
PFIZER INC. · Robo2 Esoe · 2020	Their institution	$8,883
Apellis Pharmaceuticals, Inc. · Phase II Study Assessing Safety and Efficacy of Apl-2 in Glomerulopathies · 2022	Their institution	$8,592
Travere Therapeutics, Inc. · A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With Iga Nephropathy (Protect) · 2023	Their institution	$8,312
Mallinckrodt Hospital Products Inc. · Two Part Prospective Study of H.P. Acthar Gel in the Treatment of Proteinuria Due To Idiopathis Focal Segmental Glomerulosclerosis (Fsgs) · 2020	Their institution	$8,025
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2023	This clinician	$7,969
Otsuka Pharmaceutical Co., Ltd. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study To Evaluate the Efficacy and Safety of Vis649 in Participants With Immunoglobulin A (Iga) Nephropathy · 2023	Their institution	$6,930
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2024	This clinician	$5,805
Omeros Corporation · Oms721-Gnp-001 · 2019	This clinician	$5,775
Mallinckrodt Enterprises LLC · A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel Acthar in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due To Idiopathic Membranous Nephropathy Imn · 2019	Their institution	$4,907
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Safety, Tolerability, and Efficacy of Tak-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia · 2025	This clinician	$4,800
Amgen Inc. · A Randomized, Double-Blind, Placebo-Controlled Phase 4 Clinical Trial To Evaluate the Long-Term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (Anca)-Associated Vasculitis · 2025	This clinician	$4,500
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (Ln) Or Immunoglobulin A Nephropathy (Igan) · 2024	Their institution	$4,244
PFIZER INC. · A Phase 2 12 Week Adaptive Open Label Sequential Cohort Trial To Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of Pf 06730512 Following Multiple Doses in Adult Subjects With Focal Segmental Glomerulosclerosis Fsgs · 2024	Their institution	$3,840
PFIZER INC. · A Phase 2 12 Week Adaptive Open Label Sequential Cohort Trial To Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of Pf 06730512 Following Multiple Doses in Adult Subjects With Focal Segmental Glomerulosclerosis Fsgs · 2021	Their institution	$3,379
Apellis Pharmaceuticals, Inc. · Phase II Study Assessing Safety and Efficacy of Apl-2 in Glomerulopathies · 2023	Their institution	$3,120
Alexion Pharmaceuticals, Inc. · A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (Ln) Or Immunoglobulin A Nephropathy (Igan) · 2023	Their institution	$3,077
Alexion Pharmaceuticals, Inc. · An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3g) Or Immune-Complex Membranoproliferative Glomerulonephritis (Ic-Mpgn) Treated With Ach-0144471 · 2021	Their institution	$2,944
Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy · 2025	This clinician	$2,318
Novartis Pharma AG · Cexv811a12301 · 2025	This clinician	$1,877
Genentech, Inc. · Phii Study To Examine the Effects of Obinutuzumab in Patients With Lupus Nephritis · 2019	Their institution	$556
Novartis Pharmaceuticals Corporation · Cexv811a12301 · 2025	This clinician	$548
Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Iptacopan (Lnp023) in Complement 3 Glomerulopathy · 2024	Their institution	$142
Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Iptacopan (Lnp023) in Complement 3 Glomerulopathy · 2022	Their institution	$142
Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Iptacopan (Lnp023) in Complement 3 Glomerulopathy · 2023	Their institution	$142
Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Iptacopan (Lnp023) in Complement 3 Glomerulopathy · 2025	Their institution	$142
Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Iptacopan (Lnp023) in Complement 3 Glomerulopathy · 2021	Their institution	$12

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1922141951
Licence: CA G62856California G62856: Current · expires 2027-12-31
Trained: New York Medical College, 1985
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2007-02-15
NPI last updated: 2024-04-19
NPI record certified: 2024-04-19

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: Stanford Hospital Clinics 300 Pasteur Drive, Stanford, CA, 94305